SBIR/STTR Research Award

Localized Statin Delivery for Prevention of Primary AV Fistula Failure

Award identifier 339f4c2e4339e5ac8982011d1f7eab3d3eee3026dd64f7e6395212cfc099072fAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,000

Program and phase

SBIR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AFFINITY THERAPEUTICS, LLC
Proposal award date
2017-04-01
Contract end date
2019-03-31
UEI
MVSNZ6XDQAE9
Solicitation number
PA16-302
Topic code
NHLBI

Research abstract

Abstract Summary Arteriovenous fistulas AVFs are the preferred vascular access mode for hemodialysis patients but of AVFs fail to mature and only of mature AVFs are patent after year Vascular access failure including AVFs results from neointimal hyperplasia and contributes to andgt $ billion USD annual costs from vascular access failure including of hemodialysis patient hospitalizations Systemic statin treatment is known to help prevent neointimal hyperplasia in arterial bypass grafting and recent study of patients showed a reduction in AVF failure that was strongly tied to statin identity and dose Recent evidence from Dr Sanjay Misra s lab shows that systemic statins were able to significantly reduce neointimal hyperplasia in a mouse chronic kidney disease AVF model Affinity aims to create statin loaded microparticles that can be injected into the adventitia of the venous outflow tract of the AVF to prevent neointimal hyperplasia by locally delivering statins over the course of weeks thereby eliminating potential side effects and increasing efficacy of statin action Our long term goal is to develop injectable microparticles capable of preventing neointimal hyperplasia The objective of this proposal is to produce statin loaded injectable microparticles to prevent AVF failure due to neointimal hyperplasia The central hypothesis is that localized delivery of statins over the course of several weeks will increase the lumen area of the venous outflow tract by preventing fibroblast conversion to myofibroblasts and preventing proliferation of smooth muscle cells thereby decreasing neointimal area in the venous outflow tract This work will be accomplished in three aims Validate statin loading and delivery in vitro Validate statin delivery on a model of myofibroblast differentiation using hypoxic fibroblasts in vitro and Minimize venous neointimal hyperplasia following AVF creation in vivo Our proposed work is innovative using injectable microparticles to deliver statins directly to the venous outflow tract tissue to prevent neointimal hyperplasia We use a novel approach to achieve high loading and long term sustained delivery of statins in a mode that eliminates any potential systemic side effects The expected outcomes include injectable microparticles capable of release statin for andgt days in vitro and preventing neointimal hyperplasia for at least days in vivo These results will positively impact the field of vascular access by decreasing failure rates for both AVFs and AV grafts due to neointimal hyperplasia Future work in Phase II will translate these statin loaded injectable microparticles from this Phase I proof of concept work into a statistically powerful study in pigs where the vasculature and hemodynamics are most similar to those in humans Project Narrative This proposal is critically concerned with the issue of public health in that its long term goal is to prevent primary failure of vascular access in hemodialysis patients due to neointimal hyperplasia Specifically we hope to accomplish this goal using an affinity based drug delivery system to deliver drug over a period of weeks The short term goals are to develop a microparticle formulation from affinity based polymers and to assess the efficacy of simvastatin delivery in a murine arteriovenous fistula in vivo model

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

4 SBIR/STTR records share this UEI (2012–2017). Reported award amounts total $1,151,749. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.